Serous cystadenoma (serous cystic neoplasm — SCN) is the most common benign cystic tumor of the pancreas, comprising 30-40% of all pancreatic cystic neoplasms. Typically occurs in women aged 60-70 (F:M = 3-4:1). Histologically composed of numerous small cysts (<2 cm) lined by glycogen-rich cuboidal epithelium. Malignant transformation is extremely rare (less than 1%). The tumor is usually asymptomatic and detected incidentally; large tumors (>4-6 cm) may cause mass effect symptoms (abdominal pain, early satiety). May be associated with Von Hippel-Lindau (VHL) syndrome — serous cysts in VHL patients are frequently multiple and diffuse.
Age Range
50-80
Peak Age
65
Gender
Female predominant
Prevalence
Uncommon
Serous cystadenoma is thought to originate from pancreatic centroacinar cells or ductal progenitor cells. Histologically contains numerous microcysts (<2 cm, usually <5 mm) lined by glycogen-rich, mucin-negative cuboidal epithelium. The cyst fluid is serous (clear, watery) and does not contain mucin — this feature is critical for differentiation from mucinous cystic neoplasm. The center of the tumor contains fibrous stroma and frequently a central stellate scar; calcification may develop within this scar ('sunburst calcification'). The microcystic architecture creates the 'honeycomb' pattern on imaging — numerous small cystic spaces separated by thin septa. On CT and MRI, the central scar shows enhancement and if calcified creates a 'sunburst' pattern. In VHL-associated cases, VHL gene mutation (chromosome 3p25) underlies tumor development. The pathogenetic mechanism in sporadic cases is not fully elucidated but is thought to involve the VHL gene pathway.
Star-pattern (sunburst/stellate) calcification within the central fibrous scar of the tumor. This calcification is the pathognomonic finding of serous cystadenoma and is not seen in other pancreatic cystic neoplasms. Found in approximately 30% of cases; its presence confirms the diagnosis.
Numerous small cysts (typically <5-10 mm, cyst count >6) separated by thin enhancing septa creating a 'honeycomb' pattern. Thin-section CT (<1 mm reconstruction) more clearly depicts microcysts and septa. In portal venous phase, thin septa take up contrast making inter-cystic boundaries more conspicuous. Total mass size is usually 5-12 cm but microcysts range from 1-20 mm.
Report Sentence
A well-defined mass composed of multiple small cysts separated by thin enhancing septa showing a microcystic honeycomb pattern in the pancreas is identified, consistent with serous cystadenoma.
Star-pattern (sunburst/stellate) calcification in the central portion of the tumor. This calcification develops within the central fibrous scar and is seen in ~30% of cases. It is a pathognomonic finding — distinguishes from mucinous cystic neoplasm and IPMN. Best evaluated on non-contrast thin-section CT.
Report Sentence
Sunburst pattern calcification in the central portion of the cystic mass is identified, a pathognomonic finding for serous cystadenoma.
Numerous high-signal small cysts separated by low-signal thin septa on T2-weighted images. The 'stellate honeycomb' pattern is most conspicuously visualized on T2. Central scar shows low signal on T2 (fibrosis). MRI superiority over CT lies in higher soft tissue contrast — particularly MRCP sequences add value in demonstrating small microcysts.
Report Sentence
A mass showing a honeycomb pattern composed of numerous high-signal microcysts and low-signal thin septa in the pancreas on T2-weighted images is identified.
Well-defined, lobulated contour mass with microcystic architecture. If microcysts are very small, may mimic solid appearance (pseudosolid pattern). Larger microcysts are seen as anechoic areas and inter-cystic septa appear as hyperechoic thin bands. Central scar may be seen as a hyperechoic focus. CEUS (contrast-enhanced US) can demonstrate septa and central scar enhancement.
Report Sentence
A well-defined mass with lobulated contour and microcystic architecture in the pancreas is identified; further characterization (CT/MR) for serous cystadenoma is recommended.
Microcysts showing low signal on T1-weighted images. Serous cyst fluid has composition close to simple fluid and appears hypointense on T1. As there is no hemorrhagic or proteinaceous content, T1 signal is low — this feature distinguishes from the hemorrhagic T1 hyperintensity of SPN. Post-contrast T1 fat-suppressed sequences show enhancement of septa and central scar.
Report Sentence
Microcysts with low signal on T1-weighted images are identified with post-contrast enhancement of septa and central scar, consistent with serous cystadenoma.
Criteria
Most common type (70-80%). Numerous small cysts (<2 cm, usually <5 mm), honeycomb pattern, central stellate scar.
Distinct Features
Typical honeycomb pattern easily recognized on CT and MRI. Diagnosis is definitive in the presence of central sunburst calcification. Lobulated contour and well-defined margins are characteristic.
Criteria
Contains fewer but larger cysts (>2 cm). 10-30% of all serous cystadenomas. May be confused with mucinous cystic neoplasm.
Distinct Features
Honeycomb pattern not seen — single or few large cysts. Central scar is usually absent. Cyst wall is thin and regular (mucinous neoplasm wall is thicker). Cyst fluid analysis (CEA <5 ng/mL, mucin negative) is critical for diagnosis. EUS-FNA with cytology and cyst fluid biochemistry aids in differential diagnosis.
Criteria
Multiple, bilateral pancreatic serous cysts developing in the setting of Von Hippel-Lindau syndrome. Seen in 35-70% of VHL patients.
Distinct Features
Diffuse pancreatic involvement, usually asymptomatic. Coexistence with renal cysts, renal cell carcinoma, hemangioblastoma, and pheochromocytoma. Occurs at younger age than sporadic form. Requires genetic counseling and VHL screening protocol.
Distinguishing Feature
MCN is macrocystic (few large cysts >2 cm) with peripheral eggshell calcification and thicker wall. Serous cystadenoma is microcystic with central sunburst calcification and thin wall. MCN occurs only in women and in pancreatic body/tail. Cyst fluid: MCN has high CEA (>192 ng/mL), mucin positive; serous has low CEA (<5 ng/mL), mucin negative.
Distinguishing Feature
Branch-duct IPMN shows communication with the pancreatic duct (connection visualized on MRCP), while serous cystadenoma has no ductal communication. IPMN secretes mucin and may create a 'fish-eye' appearance at the ampulla of Vater. IPMN is usually located in the uncinate process. Central scar and microcystic pattern distinguish serous cystadenoma.
Distinguishing Feature
Pseudocyst has a history of pancreatitis, typically presents as a single large unilocular cyst, and the cyst wall is composed of thick granulation tissue (no inner epithelium). Serous cystadenoma has no pancreatitis history, has multilocular microcystic architecture, and is lined by epithelium. Peripancreatic inflammatory changes and parenchymal calcifications may accompany pseudocyst.
Urgency
surveillanceManagement
conservativeBiopsy
Not NeededFollow-up
annualSerous cystadenoma is a benign tumor with negligible risk of malignant transformation (below 0.1%). When typical microcystic pattern and sunburst calcification are present, diagnosis is definitive and surgery is not needed. Active surveillance (annual MRI or CT) is sufficient for asymptomatic patients. Surgical indications: symptomatic patients (pain, obstruction), rapid growth (>0.5 cm/year), large size (>4-6 cm), inability to distinguish from mucinous neoplasm. In macrocystic variant, cyst fluid analysis via EUS-FNA (CEA, mucin, cytology) may be needed for differential diagnosis. Multidisciplinary follow-up is mandatory in VHL-associated cases.
Serous cystadenoma is a benign lesion with no malignant potential. Surveillance is sufficient for asymptomatic, small lesions. Surgery is recommended only for symptomatic lesions or diagnostic uncertainty (when indistinguishable from MCN). It may be associated with Von Hippel-Lindau syndrome.